Meeting
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
Authors
Liza C Villaruz
University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA
Liza C Villaruz , Karen Kelly , Saiama Naheed Waqar , Elizabeth J. Davis , Geoffrey Shapiro , Patricia LoRusso , Elizabeth Claire Dees , Daniel Paul Normolle , John C. Rhee , Edward Chu , Steven Gore , Jan Hendrik Beumer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02595931
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3012)
DOI
10.1200/JCO.2022.40.16_suppl.3012
Abstract #
3012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2020 ASCO Virtual Scientific Program
Phase I study of regorafenib and sildenafil in advanced solid tumors.
First Author: Andrew Stewart Poklepovic
Poster
2017 ASCO Annual Meeting
First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
First Author: Matthew Ng